The oncogenome of the domestic cat

• 成果类型: Article
• 署名作者: Francis, Bailey A.; Ludwig, Latasha; He, Chang; Dobromylskyj, Melanie; Bertram, Christof A.; Aupperle-Lellbach, Heike; Wong, Hannah; Foster, Aiden P.; Arends, Mark J.; Suarez-Bonnet, Alejandro; Priestnall, Simon L.; Tatiersky, Laetitia; Castillo-Alcala, Fernanda; Rupp, Angie; Khachadoorian, Arlene; Parlak, Eda; Inglebert, Marine; Umamaheswaran, Shevaniee; Cheema, Saamin; Del Castillo Velasco-Herrera, Martin; Wong, Kim; Vermes, Ian C.; Billington, Jamie; Rottenberg, Sven; Wood, Geoffrey A.; Adams, David J.; Van Der Weyden, Louise
• 署名单位: Wellcome Trust Sanger Institute; University of Guelph; Cornell University; University of Bern; University of Bern; University of Veterinary Medicine Vienna; LABOKLIN GmbH & Co. KG; Technical University of Munich; University of Cambridge; University of Bristol; University of Edinburgh; University of London; University of London Royal Veterinary College; Massey University; University of Glasgow; University of Bern; University of Bern
• 刊物名称: SCIENCE
• ISSN/ISSBN: 0036-8075; 1095-9203
• DOI: 10.1126/science.ady6651
• 发表日期: 2026-02-19
• 页码: 793-799
• 关键词: RAS PROTOONCOGENE MUTATIONS; SQUAMOUS-CELL CARCINOMA; PANCREATIC-CARCINOMA; FELINE LYMPHOMA; ONE MEDICINE; cancer; expression; landscape; CANINE; p53

摘要

Cancer is a common cause of morbidity and mortality in domestic cats. Because the mutational landscape of domestic cat tumors remains uncharacterized, we performed targeted sequencing of 493 feline tumor-normal tissue pairs from 13 tumor types, focusing on the feline orthologs of similar to 1000 human cancer genes. TP53 was the most frequently mutated gene, and the most recurrent copy number alterations were loss of PTEN or FAS or gain of MYC. By identifying 31 driver genes, mutational signatures, viral sequences, and tumor-predisposing germline variants, our study provides insight into the domestic cat oncogenome. We demonstrate key similarities with the human oncogenome, confirming the cat as a valuable model for comparative studies, and identify potentially actionable mutations, aligning with a One Medicine approach.